CTLA4 Antibody from ROCKLAND IMMUNOCHEMICALS INC.
Search, find, compare suppliers for anti-CTLA4 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CTLA4 |
| Clone | Abz521 |
| Host Species | Recombinant |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | Fab fragment, no preservative |
| Size | 50 µg |
| Concentration | n/a |
| Applications | ELISA, Flow Cytometry, Western Blot |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Humanized Recombinant CLTA4 Fab fragment was expressed in CHO cells. The purity was estimated to be >95% by SDS-PAGE analysis. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation - a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis. This antibody is made from a humanized Fab fragment of anti-CTLA4, ipilimumab or Yervoy, the first FDA approved immune checkpoint blockade therapy for cancer treatment. Humanized Recombinant Anti-CTLA4 fragment Antibody is useful for researchers interested in cancer research, immunodeficiency, and autoimmune diseases. |
| Immunogen | n/a |
| Other Names | Cytotoxic T-Lymphocyte Associated Protein 4, Ipilimumab, Yervoy, recombinant Monoclonal CTLA4, RabMAb CTLA4, CTLA-4, CD152, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, GSE, CD, Ligand And Transmembrane Spliced, Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4 |
| Gene, Accession # | CTLA4, Gene ID: 1493, NCBI: NP_001032720.1, UniProt: P16410 |
| Catalog # | 400-001-MT1 |
| Price | $489 |
| Order / More Info | CTLA4 Antibody from ROCKLAND IMMUNOCHEMICALS INC. |
| Product Specific References | n/a |
ROCKLAND IMMUNOCHEMICALS INC.
ROCKLAND IMMUNOCHEMICALS INC.
PO Box 5199
Limerick PA 19468
P: 484-791-3823
P: 800.656.7625
F: 484.369.8654
orders@rockland.com
Technical Support: tech@rockland.com
https://www.rockland.com/
Profile of ROCKLAND IMMUNOCHEMICALS INC.
Return to Antibodies